Abbott partners with Novo Nordisk India to launch Extensior®, broadening access to Semaglutide (Ozempic®) for advanced diabetes management

The collaboration brings together Novo Nordisk’s global GLP-1 leadership and Abbott’s strong India footprint, helping more ...
Fortune India

As semaglutide patent expiry nears, Novo Nordisk partners with Abbott to launch second brand in India

With patent protection on Danish multinational Novo Nordisk’s blockbuster GLP-1 diabetes drug semaglutide (Ozempic) set to ...
AOL

Lilly’s GLP-1 Surge Dwarfs Abbott’s Steady Device Growth With 54% Revenue Jump

Mon, December 8, 2025 at 2:21 PM UTC Abbott's medical device segment grew 14.8% to $5.45 billion. The cardiovascular portfolio drove results, with TriClip for tricuspid valve repair gaining Japan ...
Seeking Alpha

Real-World Data Show Abbott's FreeStyle Libre® Systems and GLP-1 Medicines Work Better Together for People with Type 2 Diabetes

Data analyses show that people with Type 2 diabetes using GLP-1 medicines saw a significant improvement in their HbA1C after adding FreeStyle Libre technology to their regimen Better HbA1c results ...

Abbott to sell a second brand of Novo Nordisk’s diabetes drug Ozempic

Abbott partners with Novo Nordisk to launch Extensior, a second Ozempic brand for type 2 diabetes management in India.
NDTV Profit

Abbott Partners With Novo Nordisk India To Launch Ozempic For Advanced Diabetes Management

Under the agreement between the companies, Abbott will commercialize Novo Nordisk's semaglutide (Ozempic) under the brand ...